Replies to post #225516 on Biotech Values

[DewDiligence]

Eliquis is protected from US generic competition by the ‘208 patent (http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6967208.PN.&OS=PN/6967208&RS=PN/6967208 ), which expires in Nov 2026 (https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=202155&Appl_type=N ).

Similar patents in other countries protect Eliquis until 2026.